Status:
COMPLETED
Thrice-weekly Versus Thrice-daily Oral Ferrous Fumarate Treatment in Adult Patients With Iron Deficiency Anemia
Lead Sponsor:
Prince of Songkla University
Collaborating Sponsors:
The Thai Society of Hematology
Conditions:
Iron Deficiency Anemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Iron deficiency anemia is a global health problem and the most common cause of anemia worldwide. Patients with iron deficiency and Iron deficiency anemia can present with a multitude of symptoms inclu...
Eligibility Criteria
Inclusion
- Age \>18 years
- Patients with iron deficiency anemia defined as hemoglobin less than 12 g/dL in women or 13 g/dL in men; AND ferritin less than 30 ng/mL
Exclusion
- Allergy to iron
- Currently pregnancy
- Currently breastfeeding
- Known history of inflammatory bowel disease, celiac disease, inherited bleeding disorder, solid cancer, hematologic cancer or thalassemia
- Renal impairment or glomerular filtration rate less than 30 ml/min/1.73m2
- Hepatic impairment or Child Pugh score more than 7
- Active bleeding define hemoglobin decrease more than 2 g/dL
- Multivitamin and mineral supplement (35 mg or more of elemental iron per day) in 2 weeks prior to randomization
- Non-literate
- Subject withdrawal criteria:
- Intolerance to drugs
- Active bleeding define hemoglobin decrease more than 2 g/dL
- Major surgery
- Blood transfusion
- Loss follow-up more than 2 weeks
Key Trial Info
Start Date :
January 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 18 2022
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04130828
Start Date
January 21 2020
End Date
January 18 2022
Last Update
February 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Songklanagarind Hospital
Hat Yai, Changwat Songkhla, Thailand, 90110